Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Restasis Phase 3 Study in Moderate to Severe Dry Eye Syndrome
NCT00025818Phase 3Completed
- Sponsor
- Allergan
- Start
- May 2001
- Primary completion
- Mar 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cyclosporine 2% ophthalmic solution in dry eye syndrome (DED), sponsored by Allergan. Started May 2001; status: completed.
02
Drugs
cyclosporine 2% ophthalmic solution
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT00025818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025818.